The report highlights trends prevailing in the market and factors driving its growth. The narcolepsy market growth is attributed to the rising prevalence of sleep-related neurological disorders and increasing awareness regarding neurological disorders. However, side effects and risks associated with narcolepsy medications are likely to hinder the narcolepsy market growth.

The global narcolepsy market size is estimated to reach US$ 4,537.9 million by 2027 from US$ 2,026.8 million in 2018; it is estimated to grow at a CAGR of 9.5% during 2019-2027.

North America held the largest share of the narcolepsy market in 2018 and is expected to witness a similar trend over the forecast period. The US held the largest share in North America. There are five drug treatments approved to treat patients with narcolepsy: Xyrem (sodium oxybate), Provigil (modafinil), Nuvigil (amodafonil), methylphenidate, and amphetamine. These drugs are also approved by the US Food and Drug Administration. Pitolisant, an H3R antagonist, and solriamfetol, a dopamine and norepinephrine reuptake inhibitor, are the most recently approved treatments for EDS associated with narcolepsy in the European Union (pitolisant) and the US (pitolisant and solriamfetol).

Moreover, the growth in the biopharmaceutical sector across the country is expected to support market growth during the forecast period. This sector has substantial impact on the US economy. In 2015, the biopharmaceutical industry accounted for nearly US$ 1.3 trillion in economic output, which represents 4% of total US output. This includes US$ 558 billion in revenue from biopharmaceutical businesses and US$ 659 billion from suppliers and worker spending. As per the International Trade Administration (ITA), the US is the largest market for biopharmaceuticals and is the world leader in biopharmaceutical RD. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), companies in the US conduct nearly half the world's RD in pharmaceuticals, which accounts US$ 75 billion, and have succeeded in the development of new medicine for which they hold the intellectual property rights. For instance, in 2021, SK Biopharmaceuticals received approval for its narcolepsy drug Sunosi (solriamfetol) and the drug was launched in Canada by its global business partner Jazz Pharmaceuticals. Sunosi is an FDA-approved drug to treat excessive daytime sleepiness (EDS) in adults who have narcolepsy or obstructive sleep apnea. The prescription drug was licensed out to Jazz Pharmaceuticals after Phase 1 clinical trials completed by the Korean drug developer. According to SK Biopharmaceuticals, ~15,000 people are estimated to suffer from narcolepsy in Canada and about 6.4% of its population are known to experience sleep apnea. SK Biopharmaceuticals anticipates more turnover and sales milestones and royalties from the drug with increasing market launches. The drug is distributed in major European countries, including Germany, Denmark, France, and Italy. SK Biopharmaceuticals is a license holder for Sunosi in 12 Asian countries, including South Korea, China, and Japan.

Increasing Awareness Regarding Neurological Disorders Expected to Fuel Narcolepsy Market Growth

The relationship between public health and neurology was not adequately explored until recent years. The burden of neurological disorders has increased significantly across the world. These disorders are estimated to affect over a billion population worldwide, according to the World Health Organization by 2016. Neurological disorders are commonly found among all age groups in all geographic populations. Similarly, sleep-related neurological disorders that comprise a large group of diseases also affect a substantial population worldwide. These diseases majorly include insomnia, sleep apnea, narcolepsy, and others.

However, in recent years, several measures have been undertaken to generate awareness and educate the population regarding these diseases, which is likely to propagate patients from accessing the available medications and treatments for these conditions. According to National Center for Biotechnology Information 2017, clinician and public awareness of various sleep disorders with the intent of increasing rates of recognition and treatment options is the only way to combat such sleep-related disorders.

In case of narcolepsy, the understanding of neurobiology of sleep has progressed substantially over the last several decades, as the involvement of animal models allow deeper understanding of the brain's complexities in relationship to sleep. Several local, national and international institutes, organizations and councils are undertaking measures to promote awareness regarding the disorders and availability of treatments associated with it. For instance, “Wake Up Narcolepsy” is one of the non-profit organization that seeks to raise awareness and bring direction to the search of cure for the diseases so as to support the community.

Get Sample Copy with Complete TOC and Figures Graphs @ https://www.theinsightpartners.com/sample/TIPRE00003326/

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, chemicals etc.

Contact Us:

Call: +1-646-491-9876

Email: [email protected]